These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1131 related items for PubMed ID: 15592504

  • 1. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
    Petrella BL, Lohi J, Brinckerhoff CE.
    Oncogene; 2005 Feb 03; 24(6):1043-52. PubMed ID: 15592504
    [Abstract] [Full Text] [Related]

  • 2. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH.
    Oncogene; 2000 Nov 16; 19(48):5435-43. PubMed ID: 11114720
    [Abstract] [Full Text] [Related]

  • 3. Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase.
    Petrella BL, Brinckerhoff CE.
    Mol Cancer; 2006 Dec 01; 5():66. PubMed ID: 17140440
    [Abstract] [Full Text] [Related]

  • 4. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.
    Cancer Res; 2002 Jul 01; 62(13):3803-11. PubMed ID: 12097293
    [Abstract] [Full Text] [Related]

  • 5. Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function.
    Palayoor ST, Burgos MA, Shoaibi A, Tofilon PJ, Coleman CN.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):4158-64. PubMed ID: 15217953
    [Abstract] [Full Text] [Related]

  • 6. Nur77 activated by hypoxia-inducible factor-1alpha overproduces proopiomelanocortin in von Hippel-Lindau-mutated renal cell carcinoma.
    Choi JW, Park SC, Kang GH, Liu JO, Youn HD.
    Cancer Res; 2004 Jan 01; 64(1):35-9. PubMed ID: 14729605
    [Abstract] [Full Text] [Related]

  • 7. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
    Na X, Wu G, Ryan CK, Schoen SR, di'Santagnese PA, Messing EM.
    J Urol; 2003 Aug 01; 170(2 Pt 1):588-92. PubMed ID: 12853836
    [Abstract] [Full Text] [Related]

  • 8. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Richards FM, Johnson CM, Maher ER.
    Oncogene; 2005 Jun 30; 24(28):4549-58. PubMed ID: 15824735
    [Abstract] [Full Text] [Related]

  • 9. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
    Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K, Lee S.
    Cancer Res; 2005 Jun 15; 65(12):5221-30. PubMed ID: 15958567
    [Abstract] [Full Text] [Related]

  • 10. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.
    Gunaratnam L, Morley M, Franovic A, de Paulsen N, Mekhail K, Parolin DA, Nakamura E, Lorimer IA, Lee S.
    J Biol Chem; 2003 Nov 07; 278(45):44966-74. PubMed ID: 12944410
    [Abstract] [Full Text] [Related]

  • 13. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
    Sufan RI, Jewett MA, Ohh M.
    Am J Physiol Renal Physiol; 2004 Jul 07; 287(1):F1-6. PubMed ID: 15180922
    [Abstract] [Full Text] [Related]

  • 14. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
    Kim JH, Jung CW, Cho YH, Lee J, Lee SH, Kim HY, Park J, Park JO, Kim K, Kim WS, Park YS, Im YH, Kang WK, Park K.
    Oncol Rep; 2005 May 07; 13(5):859-64. PubMed ID: 15809750
    [Abstract] [Full Text] [Related]

  • 15. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Blancher C, Moore JW, Robertson N, Harris AL.
    Cancer Res; 2001 Oct 01; 61(19):7349-55. PubMed ID: 11585776
    [Abstract] [Full Text] [Related]

  • 16. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
    Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon MC.
    Cancer Res; 2004 Dec 01; 64(23):8595-603. PubMed ID: 15574766
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.
    Zimmer M, Doucette D, Siddiqui N, Iliopoulos O.
    Mol Cancer Res; 2004 Feb 01; 2(2):89-95. PubMed ID: 14985465
    [Abstract] [Full Text] [Related]

  • 18. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
    Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ.
    Oncogene; 2000 Dec 14; 19(54):6297-305. PubMed ID: 11175344
    [Abstract] [Full Text] [Related]

  • 19. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
    Liu MY, Poellinger L, Walker CL.
    Cancer Res; 2003 May 15; 63(10):2675-80. PubMed ID: 12750296
    [Abstract] [Full Text] [Related]

  • 20. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas.
    Cuevas Y, Hernández-Alcoceba R, Aragones J, Naranjo-Suárez S, Castellanos MC, Esteban MA, Martín-Puig S, Landazuri MO, del Peso L.
    Cancer Res; 2003 Oct 15; 63(20):6877-84. PubMed ID: 14583486
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.